Pharmaceutical Cocrystals and Their Physicochemical Properties.
about
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsNon-Covalent Derivatives: Cocrystals and EutecticsPharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and DevelopmentSmall-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration.Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties.New thermoresistant polymorph from CO2 recrystallization of minocycline hydrochloride.Acemetacin cocrystal structures by powder X-ray diffraction.Early pharmaceutical evaluation of a crystalline and hygroscopic GABAB receptor agonist.Ethenzamide-gentisic acid-acetic acid (2/1/1).Resveratrol derivatives: a patent review (2009 - 2012).2-(1,3-Dioxoisoindolin-2-yl)acetic acid-N'-[(E)-2-meth-oxy-benzyl-idene]pyridine-4-carbohydrazide (1/1).2-(1,3-Dioxoisoindolin-2-yl)acetic acid-N'-[(E)-4-meth-oxy-benzyl-idene]pyridine-4-carbohydrazide (2/1).Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar SolubilizationOrganized polysaccharide fibers as stable drug carriers.Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5Hybrid nanocrystals: University of Kentucky US20060280680A1.Crystal engineering of green tea epigallocatechin-3-gallate (EGCg) cocrystals and pharmacokinetic modulation in rats.Benefits of cocrystallisation in pharmaceutical materials science: an update.New opportunities in crystal engineering--the role of atomic force microscopy in studies of molecular crystals.Cocrystallization for successful drug delivery.Selecting oral bioavailability enhancing formulations during drug discovery and development.Critical gases for critical issues: CO2 technologies for oral drug delivery.The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.Amorphous solid dispersions: a robust platform to address bioavailability challenges.Disappearing polymorphs revisited.Multicomponent Crystal Systems of Known Antimalarial Drug Molecules.Pharmaceutical cocrystals: along the path to improved medicines.Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.Pharmaceutical cocrystals: walking the talk.Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers.2-Amino-anilinium 2-carb-oxy-acetate.Process analytical techniques for hot-melt extrusion and their application to amorphous solid dispersions.Structures and physicochemical properties of vortioxetine salts.N-(2-Hy-droxy-benz-yl)adamantan-1-aminium 4-methyl-benzene-sulfonate.Do carboximide-carboxylic acid combinations form co-crystals? The role of hydroxyl substitution on the formation of co-crystals and eutectics.Nifedipine-pyrazine (2/1).Theophylline cocrystals prepared by spray drying: physicochemical properties and aerosolization performance.Propane-1,2-diaminium bis-(4-meth-oxy-benzoate).4-[3-(Pyridin-4-yl)prop-yl]pyridinium 2-carb-oxy-benzoate.
P2860
Q26779030-500C4E64-FA89-4655-9FB4-BDE5898074A9Q26796674-FE0AFB93-D846-4F8E-A860-2B05F788DD27Q28468556-3790EE8D-47D6-47EF-9439-F81CDA3CFBF1Q30375810-38E37CB0-34BB-43AA-9EE9-77C56871C516Q30669947-281441A9-C727-4CD5-A30E-F353B3B6E42AQ30824419-D75B9228-AEC8-421E-9EEA-E9AF8FBACFBBQ33630701-AE0E1F74-2858-491B-B351-7DF9E90231EAQ34173395-131B2A1E-1E56-47A7-A3A6-B7D0AD3C92B4Q34301770-FC8EDC1A-C627-4D76-8544-FFEFFA4E5664Q34986494-A3F145E3-9940-45C4-9938-DB268E08A6DFQ36149112-AA71BAF6-9129-410E-9764-49723FAC9F77Q36314177-809F727F-8392-4421-A482-2AC65EC1EE03Q36666790-C53C46C2-7A98-405A-A333-078186AE8D49Q36982139-3C991EFD-B350-4FDE-B907-B565DC151257Q37013110-EB914D0F-085E-4DAE-837E-3FD39757F856Q37093395-B4E6AAF6-4DFD-4919-883C-72A99825D36DQ37226778-FD3AB049-E82B-44A6-BEF7-EF1CBB4CBCB3Q37805586-7B5A3B8C-5846-4688-B947-6CF6A451159BQ38028473-9552695B-62B1-4705-8E98-5A391380D229Q38068972-D1135063-4D13-4357-A0B8-65736448F2FCQ38175527-FD6DEE4A-F520-4440-8F4D-24DACB28D595Q38183855-268681CE-D499-470D-B08C-94217B3D014CQ38239948-6CC5A490-688B-44A8-BC08-E19114620770Q38358879-ED08E4E3-C1CA-42DB-A308-36B87DD958C0Q38510810-570A3849-013C-4A9F-813C-34A849343582Q38586521-867C2F6F-9B24-4D76-A347-533CC52C6FEEQ38632654-C377427F-BBEB-4B6F-A96A-A9F8F6207AE9Q38787624-FF580DE8-107F-4D3E-A9AD-857CC78CA823Q38856202-D31620C8-6FE0-4610-AED7-BB81E5E723C1Q38865422-FE0F7E0F-5203-4E9F-A85F-F77747D32BCAQ38870191-093BC3F3-DAFE-4B43-902A-693287799D51Q39010328-2090988C-DEFE-4758-9404-1ACDB1753C7EQ39200871-6183E9EF-8F4A-44EB-9289-D8698C171FEFQ39326667-D01DB197-4C43-495B-840B-9580649659AFQ39821568-2D04F2C6-B224-4C43-BB3A-AFECA6E3B15AQ40296879-C79376FA-361A-427B-B1DB-FEFB28C2C900Q41404753-A6039D4F-36E2-4A7E-B9A0-4E37DCCF35ECQ41988067-9D440788-03CB-40B0-89F1-A0CE18811020Q42119772-91D8D543-CFF3-4DAF-A907-16069BB91B74Q42266140-21778A6C-C5CB-4532-9E4B-DBEC7C3E7D44
P2860
Pharmaceutical Cocrystals and Their Physicochemical Properties.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@en
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@nl
type
label
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@en
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@nl
prefLabel
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@en
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@nl
P2860
P356
P1476
Pharmaceutical Cocrystals and Their Physicochemical Properties.
@en
P2093
Ann Newman
Nate Schultheiss
P2860
P304
P356
10.1021/CG900129F
P577
2009-04-20T00:00:00Z